NeuroOne Medical Technologies (NASDAQ:NMTC) & SeaStar Medical (NASDAQ:ICU) Head to Head Survey

NeuroOne Medical Technologies (NASDAQ:NMTC) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares NeuroOne Medical Technologies and SeaStar Medical’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$3.73 million	6.58	-$11.86 million	($0.58)	-1.52
SeaStar Medical	N/A	N/A	-$26.23 million	($25.00)	-0.16

NeuroOne Medical Technologies has higher revenue and earnings than SeaStar Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

NeuroOne Medical Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.03, indicating that its share price is 203% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for NeuroOne Medical Technologies and SeaStar Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	0	0	1	0	3.00
SeaStar Medical	0	0	0	0	N/A

NeuroOne Medical Technologies presently has a consensus price target of $2.20, suggesting a potential upside of 149.97%. Given NeuroOne Medical Technologies’ higher possible upside, research analysts plainly believe NeuroOne Medical Technologies is more favorable than SeaStar Medical.

Profitability

This table compares NeuroOne Medical Technologies and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-343.55%	-277.71%	-204.28%
SeaStar Medical	N/A	N/A	-725.48%

Insider and Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 3.0% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

NeuroOne Medical Technologies beats SeaStar Medical on 9 of the 12 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.